The hepatitis therapeutics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Hepatitis Therapeutics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The hepatitis therapeutics market size has grown steadily in recent years. It will grow from $18.35 billion in 2023 to $18.89 billion in 2024 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to vaccine development, antiviral medications, public health initiatives, research funding, emerging therapies. .
The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $21.79 billion in 2028 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to continued research and development, global health efforts, shift in patient care, government initiatives, rising disease awareness.. Major trends in the forecast period include patient advocacy and support, continuous monitoring and follow-up, healthcare equity, telemedicine and remote care, focus on hepatitis c elimination..
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
Scope Of Hepatitis Therapeutics Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Hepatitis Therapeutics Market Overview
Market Drivers –
The rise in hepatitis infection globally is expected to propel the growth of the hepatitis therapeutic market going forward. The rise in hepatitis infection is due to inadequate access to healthcare and vaccinations, an increase in intravenous drug use, unsafe blood transfusion practices, and poor sanitation and hygiene conditions in some parts of the world. For instance, in April 2022, according to World Health Organization (WHO), a US-based united nations public health agency, from 11 nations, at least 169 cases of acute hepatitis of unknown origin have been documented and 350 million individuals worldwide have viral hepatitis B or C, yet for the majority, testing, and treatment are still out of reach. Therefore, the market for hepatitis therapeutics is expanding due to the rise in hepatitis infection.
Market Trends –
Product innovations have emerged as the key trend gaining popularity in the hepatitis therapeutics market. Major companies operating in the hepatitis therapeutics market are developing new products to sustain their position in the market. For instance, in November 2022, Gilead Sciences, Inc., a US-based biopharmaceutical company received approval from FDA for a medicine called Vemlidy (tenofovir alafenamide) for the treatment of paediatric patients with chronic hepatitis B virus infection. Vemlidy is a targeted prodrug of tenofovir that received FDA approval in 2016 as a once-daily treatment for individuals with chronic hepatitis B virus (HBV) infection and compensated liver disease. According to recommendations from the American Liver Foundation, it is a preferred or first-line treatment for persons with chronic HBV and compensated liver disease.
The hepatitis therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Drug Class: Oral Antivirals, Immune Modulators
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
Get an inside scoop of the hepatitis therapeutics market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=9956&type=smp
Regional Insights –
North America was the largest region in the hepatitis therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the hepatitis therapeutics market report are Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Mylan NV, Pfizer Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Biocon Biopharmaceuticals Pvt. Ltd., Zealand Pharma A/S, Zenyaku Kogyo Co. Ltd., Zosano Pharma Corporation .
Table of Contents
1. Executive Summary
2. Hepatitis Therapeutics Market Report Structure
3. Hepatitis Therapeutics Market Trends And Strategies
4. Hepatitis Therapeutics Market – Macro Economic Scenario
5. Hepatitis Therapeutics Market Size And Growth
…..
27. Hepatitis Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
